

Results of the Swiss AMI Study:

What can we achieve with stem cells?

ClinicalTrials.gov Identifier: NCT00355186

Davos; Cardiology update 2013 - 12th february 2013

Daniel Sürder, MD

Fondazione Cardiocentro Ticino


Lugano – Switzerland

daniel.suerder@cardiocentro.org


Background

Intracoronary BM-MNC infusion in the infarct related artery after AMI has been shown to be safe; however, its efficacy is still debated.

Optimal timing for cell delivery post-AMI is unknown. Previous studies indicated potential time dependent efficacy in subgroup analyses.



Study design & Methods




BM-MNC

- BM-Aspiration from the iliac crest (60ml)
- Centralized cell processing using density gradient centrifugation, without adding Heparin (*UTC Lugano*)

CMR

- Standardized protocol including cine and delayed enhancement
- Core-lab analysis (*University Hospital Zurich*)



Endpoints & sample size


Primary endpoint:


- Change in global LVEF at 4 mo. vs. baseline
 - *Assumption: Δ LVEF = 3.5%; SD of 6-7%; drop out = 10%*
 - *For a independent sample t-test 58 paired CMR per group are needed - including drop out → **n = 64 per group***

Secondary endpoints:

- Change in LV volumes, infarct size (DE CMR) and regional myocardial thickening
- MACE (death, MI, coronary revascularization, stroke)
- Predictors for efficacy (time to reperfusion, transmural, microvascular obstruction)

Patient flow chart






Baseline characteristics of the patients

	Control (n = 67)	Early (n = 65)	Late (n = 63)	p-value
Age – years (median; IQR)	56 (14.5)	55 (15)	62 (15)	0.70 * 0.06 ‡
BMI - kg/m2 (median; IQR)	26.7 (4.4)	27.0 (6.1)	27.0 (4.4)	0.92 * 0.89 ‡
Male gender - %	83.6	86.2	82.5	0.18 * 1.00 ‡
Hypertension - %	43.3	49.2	38.7	0.60 * 0.72 ‡
Hyperlipidemia - %	44.8	40.0	41.9	0.60 * 0.86 ‡
Diabetes - %	17.9	7.7	9.7	0.12 * 0.21 ‡
Smoking (active/previous) - %	62.7	67.7	40.3	0.60 * 0.01 ‡
Familial history of CAD - %	35.8	26.1	24.2	0.26 * 0.18 ‡
1 / 2 / 3 vessel disease %	64/21/15	54/32/14	57/27/16	0.34 * 0.73 ‡
Previous PCI before AMI - %	3.0	3.1	1.6	1.00 * 1.00 ‡

* control vs. early
‡ control vs. late



Characteristics of index AMI

	Control (n = 67)	Early (n = 65)	Late (n = 63)	p-value
Primary PCI – %	94.0	98.5	100.0	0.37 * 0.12 ‡
Concomitant PCI other than infarct related artery – %	18.2	12.3	11.1	0.47 * 0.32 ‡
Infarct vessel LAD/LCX/RCA -%	89/3/8	95/2/3	92/3/5	0.51 * 0.89 ‡
Pain to revascularization time (h)	4.5 (5)	4.8 (5.4)	4.0 (4.8)	0.57 * 0.53 ‡
Stent diameter (mm)	3.5 (0.5)	3.0 (0.5)	3.5 (0.5)	0.73 * 0.89 ‡
Drug eluting stent – %	71.6	80.0	81.0	0.31 * 0.23 ‡
TIMI flow before/after PCI	0/3 (0/0)	0/3 (0/0)	0/3 (0/0)	0.31/0.94 * 0.87/0.81 ‡
Use of Glycoprotein IIb/IIIa inhibitors / bivalirudin - %	71.7	78.5	78.1	0.88 * 0.20 ‡
Maximal creatin kinase - U/l (median;IQR)	3671 (3685)	4314 (3561)	3436 (3813)	0.22 * 0.78 ‡
Baseline nt-pro BNP - ng/l (median;IQR)	1103 (1848)	1450 (1442)	1581 (1912)	0.15 * 0.10 ‡
Baseline LVEF - % (median;IQR)	39.6 (11.2)	34.6 (16.1)	35.6 (11.2)	0.07 * 0.03 ‡
Baseline LVEDV – ml (median;IQR)	154 (44)	153 (49)	149 (47)	0.89 * 0.96 ‡
Baseline LVESV – ml (median;IQR)	94 (35)	94 (41)	97 (38)	0.54 * 0.41 ‡

* control vs. early
‡ control vs. late

Characteristics of BM-MNC


	Early n = 62	Late n = 52	p-value (between group difference)
Cell characteristics (Median, IQR)			
BM aspiration volume (ml)	65 (15)	70 (15)	0.30
Total MNC (10^6 cells)	159.7 (125.8)	139.5 (120.5)	0.18
Viability - %	93.6 (5.55)	93.33 (6.60)	0.98
% CD 34+ cells	1.02 (0.72)	1.31 (0.97)	0.01 #
Total CD 34+ cells (10^6 cells)	1.6 (1.69)	1.45 (2.43)	0.68
% CD 133+ cells	82.65 (28.1)	78.45 (52.83)	0.34
Total CD 133+ cells (10^6 cells)	0.96 (1.46)	0.92 (2.06)	0.77
% Invasion	33 (18) *	26.5 (16.5) **	0.18
Invasion index	50.88 (24.38) *	45.64 (22.10) **	0.21
Timing of BM-MNC treatment			
Days after AMI (Median, IQR)	6 (2)	24 (7)	NA


* n = 29

** n = 30

Results


Mean LVEF at baseline and 4 months






Primary Endpoint

Mean change in LVEF 4 months vs. baseline






Secondary Endpoints

Change in LV-volumes 4 months vs. baseline

LVEDV (ml)

$P = 0.03$ vs. control


$P = 0.89$ vs. control



LVESV (ml)

$P = 0.07$ vs. control

$P = 0.79$ vs. control




Secondary Endpoints

Change in scar size and regional LV function

Scar size (g)

$P = 0.59$ vs. control


$P = 0.82$ vs. control



Myocardial thickening in the infarct territory (mm)


$P = 0.67$ vs. control


$P = 0.54$ vs. control



Predictors for treatment efficacy

Change
in LVEF





Clinical events during follow up

	Control	Early	Late	p-value
Events between randomization and therapy				
Death	0	1 (3.1%)	1 (1.7%)	0.24 * 0.48 ‡
Events at 4 months follow up (cumulative)				
Death	0	3 (4.8%)	1 (1.7%)	0.24 * 0.48 ‡
Myocardial infarction	1 (1.6%)	1 (1.6%)	0	1.00 * 1.00 ‡
Rehospitalization for heart failure	2 (3.2%)	0	2 (3.6%)	0.50 * 1.00 ‡
Revascularization	3 (4.8%)	3 (4.9%)	2 (3.6%)	1.00 * 1.00 ‡
Cerebral infarction	1 (1.6%)	1 (1.7%)	0	1.00 * 1.00 ‡
Combined events				
Death, myocardial infarction, revascularization, rehospitalization for heart failure	4 (6.4%)	5 (7.9%)	5 (8.8%)	1.00 * 0.74 ‡
Death, myocardial infarction, revascularization, rehospitalization for heart failure, stroke	4 (6.4%)	6 (9.5%)	5 (8.8%)	0.74 * 0.74 ‡


* control vs. early
‡ control vs. late

	Difference in Mean	95% Confidence Interval	<i>P</i> for <i>Z</i>	<i>P</i> for Subgroup Differences
LVEF				
Echo	3.61	2.18 to 5.04	<0.00001	0.001
SPECT	2.60	−0.35 to 5.55	0.08	
MRI	1.17	−0.60 to 2.95	0.20	
LVG	7.08	4.77 to 9.38	0.0001	


SWISS AMI: Δ LVEF
early vs. control = 2.1%

Adapted from Jeevanantham et al. Circulation 2012

Subgroup analysis indicates potential benefit of i.c. BM-MNC in patients with early reperfusion (within 4.5 h from the onset of pain).





Preliminary long term results



Kaplan-Meier estimate for Overall survival


Grouping variable: group / p-value logrank = 0.59






Kaplan-Meier estimate for coronary revascularization


Grouping variable: group / p-value logrank = 0.46






Kaplan-Meier estimate for combined EP


Grouping variable: group / p-value logrank = 0.41




Biomarkers overall 3 groups




Biomarkers early treatment group




Biomarkers late treatment group



Biomarkers control group





Acknowledgements

PI: Roberto Corti
Co-PI: Daniel Sürder

CMR core lab:

Robert Manka
Juerg Schwitter
Valentin Gisler
Florian Mayer
Christina Scheiben

USZ:

Ines Bühler
Simone Kaufmann

Sebastian Stoll
Christoph Wyss
Manuel Zipponi

CCT / UTC core lab:

Tiziano Moccetti
Lucia Turchetto
Sabrina Soncin
Viviana Lo Cicero
Marina Radrizzani
Giuseppe Astori
Elena Pecchi

Inselspital:

Aris Moschovitis
Stephan Windecker
Andreas Wahl
Christa Schönenberger

KS Luzern:

Paul Erne
Michel Zuber
Christof Auf der Maur
Peiman Jamshidi
Doris Erne
Brigitta Mehmman



**UniversitätsSpital
Zürich**



CARDIOCENTROTICINO



**Kantonsspital
Luzern**



INSELSPITAL

UNIVERSITÄTSSPITAL BERN
HOPITAL UNIVERSITAIRE DE BERNE